Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | F13A1 | P00488 | 1/20 | 0.30 |
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
| ▸ | TGM1 | P22735 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9020181 | 1.00 | HSD11B1 (0.32) | HSD11B1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL9611275 | 1.00 | HSD11B1 (0.32) | HSD11B1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL1923745 | 1.00 | HSD11B1 (0.32) | HSD11B1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL143729 | 0.83 | CHRM2 (0.34) | HSD11B1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL142993 | 0.83 | CHRM2 (0.34) | HSD11B1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL15632355 | 0.83 | NR1H2 (0.36) | CHRM2CHRM1CHRM3 | |
| SCHEMBL1882303 | 0.83 | NR1H2 (0.36) | CHRM2CHRM1CHRM3 | |
| SCHEMBL15632374 | 0.83 | NR1H2 (0.36) | CHRM2CHRM1CHRM3 | |
| SCHEMBL573307 | 0.83 | NR1H2 (0.36) | CHRM2CHRM1CHRM3 | |
| SCHEMBL141264 | 0.83 | NR1H2 (0.36) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415486-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120135990-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
| EP-2328412-A1 | IAP INHIBITORS | Tetralogic Pharmaceuticals Corp. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010033531-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | HSD11B1 4339/4885CHRM2 4448/4885CHRM1 4405/4885 |
| US-20120135990-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | HSD11B1 4339/4885CHRM2 4448/4885CHRM1 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.